FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

Related Categories:

Drug, Bio-affecting And Body Treating Compositions


Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)



Ige antibodies for the inhibition of tumor metastasis
12/18/14 - 20140370001 - The present invention provides novel IgE antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing...

Methods for the treatment of gout
12/18/14 - 20140370002 - Disclosed are methods for the treatment and/or prevention of gout, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof....

Process for concentration of antibodies and therapeutic products thereof
12/18/14 - 20140370003 - The present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process for preparing highly concentrated antibody compositions, and highly concentrated antibody products....

Method of boosting the immune response in neonates
12/18/14 - 20140370004 - In an aspect, a method of augmenting an immune response in a subject in need thereof, comprising identifying the subject, and treating the subject to inhibit the immune suppressive effect of CD71+ cells is provided. Further provided is a method of preventing, treating or ameliorating an infection in a subject,...

Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
12/18/14 - 20140370005 - The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity...

Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
12/18/14 - 20140370006 - The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity...

Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof
12/18/14 - 20140370007 - This disclosure generally relates to cell-based therapies for treatment of visual disorders, including disorders of the cornea. Methods are exemplified for directed differentiation of corneal cells from stem cells. Compositions of corneal endothelial cells and uses thereof are also provided. Exemplary compositions exhibit improved cell density and/or more “youthful” gene...

Thrombin-binding antibody molecules and uses thereof
12/18/14 - 20140370008 - This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin....

Therapeutic nanoparticles and methods of use thereof
12/18/14 - 20140370009 - Provided herein are therapeutic nanoparticles having a diameter of between 10 nm to 30 nm, and containing a polymer coating, and a nucleic acid containing a sequence complementary to a sequence within a micro-RNA identified as having a role in cancer cell metastasis or anti-apoptotic activity in a cancer cell...

Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
12/18/14 - 20140370010 - The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders....

Methods of treating or preventing cognitive impairment using indane acetic acid derivatives
12/18/14 - 20140370011 - The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of cognitive disorders....

Peptide compounds for inhibition of platelet aggregation
12/11/14 - 20140363423 - The invention relates to a peptide compound and its pharmaceutical composition for inhibiting platelet aggregation and preventing/treating thrombogenic diseases. The invention develops pentapeptides and hexapeptides derived from snake venom C-type lectin-like proteins (CLPs) fragments, which can inhibit platelet aggregation and have antithrombotic activity without hemorrhagic tendency. Accordingly, they can be...

Use of chimeric anti-cd20 antibody as in vitro or in vivo purging agent in patients receiving bmt or pbsc transplant
12/11/14 - 20140363424 - The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients....

Systems and methods for identifying cancers having activated progesterone receptors
12/11/14 - 20140363425 - Systems and methods for identifying tumors having activated progesterone receptors are provided. Patients suspected of having a tumor susceptible to growth inhibition by anti-progestins can be treated with an anti-progestin....

Heterodimeric proteins
12/11/14 - 20140363426 - In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and...

Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
12/11/14 - 20140363427 - Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically...

Therapeutic antigen-binding molecule with a fcrn-binding domain that promotes antigen clearance
12/11/14 - 20140363428 - The present invention provides: a modified FcRn-binding domain having an enhanced affinity for the Fc Receptor neonatal (FcRn) at neutral pH; an antigen-binding molecule comprising said FcRn-binding domain, which has low immunogenicity, high stability and form only a few aggregates; a modified antigen-binding molecule having an increased FcRn-binding activity at...

Binding molecules specific for her3 and uses thereof
12/11/14 - 20140363429 - The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and...

Biomarkers of resistance to her2 inhibitors
12/04/14 - 20140356349 - Provided is a method of suppressing resistance to an anticancer drug, comprising administering an inhibitor of expression or activity of ECM 1 (Extracellular Matrix Protein 1) to a cancer cell or an individual with cancer....

Combination therapy to prevent dcis formation and progression to breast cancer
12/04/14 - 20140356350 - A method of treating a ductal carcinoma in situ (DCIS) lesion in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of a first agent capable of down-regulating activity and/or expression of at least one component participating in a NOTCH pathway,...

Methods of treating progressive forms of multiple sclerosis
12/04/14 - 20140356351 - The present disclosure relates to methods of treating individuals suffering from progressive forms of multiple sclerosis....

Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate
12/04/14 - 20140356352 - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD79b antibody-drug conjugate....

Targeted binding agents against b7-h1
12/04/14 - 20140356353 - Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed....

Therapy for filovirus infection
12/04/14 - 20140356354 - The present invention addresses a need for improved treatments for filovirus infections....

Il-17 receptor a antigen binding proteins
12/04/14 - 20140356355 - The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to...

Use of il-1 beta binding antibodies
12/04/14 - 20140356356 - The present invention relates to an IL-1β binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event....

Compounds and methods for treating inflammatory diseases
12/04/14 - 20140356357 - A monoclonal secretory IgA antibody, which binds to and neutralizes human TNFα. The secretory antibody is useful in treating a variety of inflammatory conditions in humans....

Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
12/04/14 - 20140356358 - Described herein are variant Fc-fragments that contain an insertion within or adjacent to a loop that bind to the neonatal Fc receptor (FcRn) with higher affinity and/or higher binding activity at pH 5-6 and approximately the same or lower affinity at a physiologic pH as compared to a control Fc-fragment,...

Human growth hormone receptor antagonist antibodies and methods of use thereof
12/04/14 - 20140356359 - The present invention provides antagonizing antibodies that bind to growth hormone receptor (GHR). The invention further relates to therapeutic methods for use of these antibodies to reduce IGF-1 levels and/or for the treatment and/or prevention of diseases associated with excessive IGF-1, including treatment of acromegaly, gigantism, cancer, diabetic nephropathy, arthritis,...

Piperazinyl derivatives for the treatment of cancer
12/04/14 - 20140356360 - The present invention relates to piperazinyl derivatives of formula (I) and the use thereof as a drug, particularly for the treatment of cancer, the pharmaceutical compositions containing said derivatives, and the method for synthesising same....

Methods of treating cancer
11/27/14 - 20140348819 - The present invention provides methods of treating cancer....

Immunoglobulins with reduced aggregation
11/27/14 - 20140348820 - The present disclosure relates to immunoglobulins with reduced aggregation and compositions, methods of generating such immunoglobulins with computational tools and methods of using such immunoglobulins particularly in the treatment and prevention of disease....

Defective mismatch repair and benefit from bevacizumab for colon cancer
11/27/14 - 20140348821 - Methods of testing to identify and to treat a subset of colon cancer patients exhibiting dMMR tumor tissue, who derive significant clinical benefit from the addition of bevacizumab to standard adjuvant chemotherapy. The presence of a V600E BRAF mutation is also of significance....

Methods and compositions to treat and detect misfolded-sod1 mediated diseases
11/27/14 - 20140348822 - The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1)...

Histone deacetylase (hdac) inhibitors for the treatment of cancer
11/27/14 - 20140348823 - The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a...

Novel complex mutations in the epidermal growth factor receptor kinase domain
11/20/14 - 20140341884 - New mutations were found in exon 19 of the EGFR gene, the exon that is often mutated in tumors. The invention comprises methods of detecting the mutations, methods of prognosis and methods of predicting response to treatment based on the presence of absence of the mutations....

Formulation for anti-alpha4beta7 antibody
11/20/14 - 20140341885 - Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy...

Treatment with anti erbb2 antibodies
11/20/14 - 20140341886 - The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or...

Methods for treating, diagnosing, and monitoring rheumatoid arthritis
11/20/14 - 20140341887 - Methods of identifying, diagnosing, and prognosing rheumatoid arthritis are provided, as well as methods of treating rheumatoid arthritis. Also provided are methods for identifying effective rheumatoid arthritis therapeutic agents and predicting responsiveness to rheumatoid arthritis therapeutic agents....

Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
11/20/14 - 20140341888 - The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited...

Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
11/20/14 - 20140341889 - The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited...

Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
11/20/14 - 20140341890 - The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited...

Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
11/20/14 - 20140341891 - The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited...

Anti-alpha2 integrin antibodies and their uses
11/20/14 - 20140341892 - The invention relates to anti-α2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of α2 integrin and inhibit the interaction of α2β1 integrin with collagen. Also disclosed are therapeutic uses of anti-α2 integrin antibodies in treating α2β1-mediated disorders, including anti-α2 integrin antibodies that...

Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
11/20/14 - 20140341893 - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood...

Certain chemical entities, compositions and methods
11/20/14 - 20140341894 - Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein....

Pseudomonas aeruginosa oprm epitopes for use in diagnostics and therapeutics
11/20/14 - 20140341895 - The present invention relates to a peptide antigens derived from Pseudomonas aeruginosa outer membrane protein OprM for use in the diagnosis of Pseudomonas aeruginosa infection and/or prevention/treatment of diseases associated with Pseudomonas aeruginosa infection. Methods of inducing an immune response to Pseudomonas aeruginosa using peptide antigens derived from the OprM...

Humanized anti-human nkg2a monoclonal antibody
11/20/14 - 20140341896 - The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies....

Anti-folate receptor alpha antibodies and uses thereof
11/20/14 - 20140341897 - Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing cancers,...

Silent fc variants of anti-cd40 antibodies
11/20/14 - 20140341898 - The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation....

Immunoglobulin constant region fc receptor binding agents
11/13/14 - 20140335075 - IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are...

Humanized monoclonal antibodies to hepatocyte growth factor
11/13/14 - 20140335076 - The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient....

Compositions and methods for the treatment of cancer using igf-ir antagonists and mapk/erk inhibitors
11/13/14 - 20140335077 - The present invention relates generally to the field of cancer therapy. More specifically the present invention relates a combination therapy where IGF-1R antagonists are combined with MAPK/ERK pathway inhibitors. The present invention relates to a therapeutic combination comprising an IGF-1R antagonist and a MAPK/ERK pathway inhibitor, and to methods for...

Use of complement inhibitors to treat ocular diseases
11/13/14 - 20140335078 - The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole...

Solenopsin and derivatives, therapeutic compositions, and methods related thereto
11/13/14 - 20140335079 - or salts, esters or prodrugs thereof as described herein....

Ester derivatives of androgen receptor modulators and methods for their use
11/13/14 - 20140335080 - or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, J1, J2, X, Z, n1 and n2 are as defined herein, and wherein at least one of R1, R2 or R3 is an alkyl, alkenyl, aryl or aralkyl ester, are provided. Uses of such compounds...

Treatment for rheumatoid arthritis
11/13/14 - 20140335081 - Treatment of rheumatoid arthritis (RA) to provide clinical benefit in patients, including decrease in DAS28-CRP by more than 1.2 and/or improvement determined by ACR20, ACR50 or ACR70, comprising administering therapeutic antibody mavrilimumab or other inhibitor targeted to Tyr-Leu-Asp-Phe-Gln motif of granulocyte/macrophage colony stimulating factor receptor alpha (GM-CSFRα). Use of GM-CSFRα...

Combination therapy comprising an mmp-14 binding protein
11/13/14 - 20140335082 - Proteins that bind to matrix metalloproteinase 14, combination therapies with such proteins and methods of using such proteins are described....

Methods of treatment and prevention of eye diseases
11/13/14 - 20140335083 - The present invention provides compositions and methods useful for treating and preventing neovascular AMD by inhibition of CCR3. The compositions and methods are useful for treating and preventing diseases and disorders such as but not limited to, neovascular AMD...

Antibody formulation
11/13/14 - 20140335084 - The present invention relates to an anti-CD44 monoclonal antibody formulation, a process for the preparation of said formulation and uses thereof....

Use of therapeutic compositions comprising hyaluronan and therapeutic antibodies
11/06/14 - 20140328828 - The present invention relates generally to treatment and prophylactic protocols for cellular disease or disorders, such as diseases and disorders associated with abnormal cellular proliferation. More particularly, the present invention provides uses of compositions comprising therapeutic antibodies and hyaluronan in the treatment or prophylaxis of cellular diseases and disorders....

Agr2 blocking antibody and use thereof
11/06/14 - 20140328829 - Disclosed is an AGR2 blocking monoclonal antibody, and in particular, a humanized monoclonal antibody for blocking AGR2. Also disclosed is a pharmaceutical composition containing the antibody and a method for preparing the same, and a use of the antibody in blocking tumor growth and metastasis....

Anti-integrin beta-1 antibody compositions and methods of use thereof
11/06/14 - 20140328830 - The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin β1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer....

Single domain tdf-related compounds and analogs thereof
11/06/14 - 20140328831 - The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders....

Methods for treating cancer using combination therapy
11/06/14 - 20140328832 - Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a substituted quinazolinone compound and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide to a patient having a cancer....

Methods for treating cancer using anti-pd-1 antibodies
11/06/14 - 20140328833 - The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions...

Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitor
11/06/14 - 20140328834 - A pharmaceutical combination comprising an Hsp90 inhibitor and an HER2 inhibitor, and methods of using the combination to treat proliferative disorders....

Methods for treating retinopathy with extended therapeutic effect
11/06/14 - 20140328835 - Methods for treating and preventing retinopathic conditions by administering an anti-VEGF compound to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy....

Her2/neu-specific antibodies and methods of using same
11/06/14 - 20140328836 - This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such...

Affinity peptides toward infliximab
11/06/14 - 20140328837 - We have disclosed affinity peptides toward infliximab. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for infliximab....

Caninised antibodies and method for production of same
11/06/14 - 20140328838 - A method of producing a non-immunogenic immunoglobulin for administration to a target species is provided wherein the method comprises substituting amino acid residues in framework regions of a donor immunoglobulin with amino acid residues present at a corresponding position in framework regions of at least one immunoglobulin derived from the...

Methods for reducing the frequency and severity of acute exacerbations of asthma
11/06/14 - 20140328839 - Provided herein is are methods of reducing the number and severity of acute exacerbations of asthma in an asthma patient, comprising administering to a patient with a history of acute exacerbations of asthma an effective amount of an anti-interleukin-5 receptor (IL-5R) antibody or antigen-binding fragment thereof, for example, an anti-IL-5Rα...

Marker and target for responsiveness and resistance to cancer agents
11/06/14 - 20140328840 - An assay of identifying the responsiveness of a HER2-positive cancer in a patient to a HER2 targeted drug, the method comprising the step of comparing a level of NeuromedinU in a biological sample obtained from the patient with a reference level of NeuromedinU, wherein detection of a level of NeuromedinU...

Anti-ceacam1 recombinant antibodies for cancer therapy
11/06/14 - 20140328841 - Provided herein are recombinant monoclonal antibodies and antigen-binding portions thereof useful in inhibiting CEACAM1 in tumor cells, and methods of their use in anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, particularly pancreatic cancer....

Predicting responsiveness to antibody maintenance therapy
11/06/14 - 20140328842 - Methods, reagents and kits are provided for predicting whether an individual suffering from an antibody dependent cell-mediated cytotoxicity (ADCC)-treatable disease is responsive to an antibody maintenance therapy. The methods, reagents, and kits find a number of uses, including, for selecting individuals who will be responsive for treatment with an antibody...